Tetra Bio-Pharma Inc., of Ottawa, said it partnered with an undisclosed manufacturer of controlled active pharmaceutical ingredients in the U.S. for the manufacturing of Dronabinol XL Adversa, as the company accelerates plans to submit a 505(b)(2) NDA for the treatment of chemotherapy-induced nausea and vomiting and anorexia associated with weight loss in patients with AIDS. Tetra licensed the technology in March from Intelgenx Pharmaceuticals Inc., of Saint Laurent, Quebec.